Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Prostatic Neoplasms 9Glioblastoma 9Carcinoma, Non-Small-Cell Lung 7Lung Neoplasms 6Brain Neoplasms 6Glioma 5Breast Neoplasms 5Oligodendroglioma 4Neoplasm Metastasis 4Multiple Myeloma 4Colorectal Neoplasms 4Astrocytoma 4Squamous Cell Carcinoma of Head and Neck 3Pancreatic Neoplasms 3Neuroectodermal Tumors, Primitive 3Neoplasms 3Meningioma 3Medulloblastoma 3Gliosarcoma 3Glioma, Subependymal 3Ependymoma 3Central Nervous System Neoplasms 3Carcinoma, Renal Cell 3Sarcoma 2Platinum-Refractory Fallopian Tube Carcinoma 2Pinealoma 2Melanoma 2Lymphoma, Mantle-Cell 2Lymphoma 2Hematologic Neoplasms 2

Interventions

X-Rays 1Vorinostat 1Sorafenib 1Magnetic Resonance Spectroscopy 1Erlotinib Hydrochloride 1Curcumin 1Cetuximab 1AH 111585 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Advanced Cancers × Magnetic Resonance Spectroscopy × Clear all
NCT02193672 2014-07-18

A Pilot, Exploratory, Non-Randomized Study of PET/CT With the Investigational Agent [18F] Fluciclatide to Correlate With Response to Anti-Cancer Therapy

M.D. Anderson Cancer Center

Phase 1 Withdrawn

Advanced Cancers

Data powered by HemOnc (CC BY 4.0) Colophon âš¡